[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

van Nuenen et al., 2005 - Google Patents

The effect of anti-TNF-α antibody therapy in Crohn's disease on composition and activity of faecal microbiota: a pilot study

van Nuenen et al., 2005

View PDF
Document ID
13688616680683703106
Author
van Nuenen M
van der Woude J
Venema K
Welling G
Harmsen H
van der Schaaf S
Kuipers E
Publication year
Publication venue
Composition and Activity of Gut Microbiota in Inflammatory Bowel Disease

External Links

Snippet

We aimed to determine whether anti-TNF-α monoclonal antibody therapy for Crohn's disease (CD) has an effect on the composition of the faecal microbiota in these patients. It was hypothesized that if the microbial composition correlates with clinical disease activity …
Continue reading at repub.eur.nl (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Micro-organisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor

Similar Documents

Publication Publication Date Title
US20210106629A1 (en) Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
EP3468573B1 (en) Treatment of clostridium difficile infection
Malo et al. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates
JP6954563B2 (en) Use of pasteurized Akkermansia to treat metabolic disorders
CN113293113B (en) Bifidobacterium longum MI-186 and application thereof
US20220313754A1 (en) Bifidobacterium lactis bl-99 and application thereof
CA2810698A1 (en) Aryl hydrocarbon receptor-activating probiotics for preventing inflammation
US11833178B2 (en) Bifidobacterium longum for treating obesity and weight management
CN113234640A (en) Bifidobacterium longum MF-269 and application thereof
JP2022547330A (en) Compositions and methods for treating autism spectrum disorders
Teng et al. An early fecal microbiota transfer improves the intestinal conditions on microflora and immunoglobulin and antimicrobial peptides in piglets
US20200164000A1 (en) Compositions and methods for treating disorders related to a gut dysbiosis
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
CN113337440A (en) Lactobacillus salivarius MG-587 and application thereof
JP2006180836A (en) Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same
JP2021526526A (en) Composition containing a bacterial strain
EP4306118A1 (en) Composition and ameliorating agent having inflammation reducing effect
van Nuenen et al. The effect of anti-TNF-α antibody therapy in Crohn’s disease on composition and activity of faecal microbiota: a pilot study
EP4384206A1 (en) Aldehyde dehydrogenase producing bacteria and methods of using same
AU2022341608A1 (en) Use of bacillus amyloliquefaciens for preventing and treating parkinson's disease
CN111132684A (en) Twin blood cocci as biotherapeutic agents
JP2019045353A (en) Method for detecting change of intestinal bacterial flora by using aquapolin as index
TW202140049A (en) Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
Gancarčíková et al. Antibiotic-treated SPF mice as a gnotobiotic model
Nikolić Diabetes mellitus and obesity as a result of a disrupted homeostatic microbiome. New data on etiopathogenesis of diabetes mellitus